Copertina

New approaches in gene therapy for sickle cell disease, moving in vivo

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	David G. Kent
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”
Pubblicazione: (2024)

Inflammatory pathways and anti‐inflammatory therapies in sickle cell disease
di: Karina Tozatto‐Maio, et al.
Pubblicazione: (2024)

Can health inequalities in sickle cell disease be addressed through novel therapies?
di: Stephen P. Hibbs, et al.
Pubblicazione: (2025)

News on sickle cell disease: Heme‐driven disordered erythropoiesis
di: Francesca Vinchi
Pubblicazione: (2024)

Cellular therapies for sickle cell disease: Should we be calling them a cure?
di: Lydia O. Okoibhole, et al.
Pubblicazione: (2025)

Examining the secret life of the spleen in sickle cell disease
di: Adama Ladu, et al.
Pubblicazione: (2025)

Know your blood: Addressing barriers to preconceptual screening for sickle cell disease
di: Ernel Boadi, et al.
Pubblicazione: (2025)

Waiting and seeing: The importance of long‐term system‐wide monitoring of mouse models of disease
di: David G. Kent
Pubblicazione: (2025)

Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension
di: Francesca I. Cendali, et al.
Pubblicazione: (2026)

Cerebral hemodynamics and oxygen metabolism in patients with milder and severe forms of sickle cell disease and thalassemia
di: Liza Afzali‐Hashemi, et al.
Pubblicazione: (2024)

Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state
di: Marc Romana, et al.
Pubblicazione: (2024)

Elevated serum heme oxygenase‐1 in pediatric sickle cell disease: Insights from the SickleGenAfrica Network
di: Anna M. Sowa, et al.
Pubblicazione: (2025)

Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: A mixed‐methods, prospective cohort study
di: Elisabeth Dovern, et al.
Pubblicazione: (2025)

Lower efficacy of transfusion of red blood cells from donors with sickle cell trait
di: Monika Dzieciatkowska, et al.
Pubblicazione: (2026)

He shoots, he scores: Navigating the complex world of transcriptomic scores in the age of artificial intelligence
di: David G. Kent
Pubblicazione: (2024)

In vivo CAR therapies: Turning the patient into their own CAR factory
di: François Vilcot, et al.
Pubblicazione: (2026)

MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients
di: Ariel Koren, et al.
Pubblicazione: (2026)

Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
di: Mariana Bastos‐Oreiro, et al.
Pubblicazione: (2025)

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
di: Maeve A. O'Reilly, et al.
Pubblicazione: (2024)

From hypoxia single‐cell gene signatures to HIF targeting of AML leukemic stem cells
di: Thomas Mercher, et al.
Pubblicazione: (2024)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
di: Sophia Stock, et al.
Pubblicazione: (2025)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
di: Patrick Born, et al.
Pubblicazione: (2025)

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
di: Gloria Iacoboni, et al.
Pubblicazione: (2024)

Preliminary evidence of CAR T‐cell therapy activity in vitreoretinal lymphomas: An LOC network study
di: Cécile Pivert, et al.
Pubblicazione: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
di: Martijn W. C. Verbeek, et al.
Pubblicazione: (2025)

Outcomes and treatment patterns of patients with primary mediastinal B‐cell lymphoma after CAR‐T cell therapy failure: A DESCAR‐T analysis
di: Jean Galtier, et al.
Pubblicazione: (2025)

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
di: Baptiste Le Calvez, et al.
Pubblicazione: (2024)

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
di: Inna Y. Gong, et al.
Pubblicazione: (2024)

Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe
di: Florence Broussais, et al.
Pubblicazione: (2025)

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
di: Pierre Sesques, et al.
Pubblicazione: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
di: Anna Ossami Saidy, et al.
Pubblicazione: (2025)

Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells
di: Gloria Iacoboni, et al.
Pubblicazione: (2024)

Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA
di: Amira Marouf, et al.
Pubblicazione: (2025)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
di: Prashant R. Tembhare, et al.
Pubblicazione: (2024)

Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study
di: Philipp Berning, et al.
Pubblicazione: (2024)

Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia
di: Rosita Del Prete, et al.
Pubblicazione: (2024)

Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee
di: Nick van Sinderen, et al.
Pubblicazione: (2025)

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
di: Anna Pia Enblad, et al.
Pubblicazione: (2025)

Fetal‐hemoglobin‐expressing red blood cells (“F cells”) consist of three distinct types as revealed by single‐cell transcriptomic analysis of circulating reticulocytes
di: Helen Rooks, et al.
Pubblicazione: (2025)

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients
di: Caroline Diorio, et al.
Pubblicazione: (2026)